US pharma giant Eli Lilly, Insilico Medicine secure deal worth $2.75 billion to bring AI-developed drugs to market

US pharmaceutical giant Eli Lilly has reached a deal worth $2.75 billion with Insilico Medicine. Under the agreement, Lilly will bring AI-developed drugs to the global market, while Insilico will receive $115 million upfront, with the remainder tied to regulatory approvals and commercial milestones

Go to News Site